{"url_path":"/sec/aktx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","accession_number":"0001493152-26-024446","cik":"0001541157","ticker":"AKTX","issuer_name":"Akari Therapeutics Plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","primary_entity_key":"0001541157","primary_entity_name":"Akari Therapeutics Plc"},"word_count":309,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n31.1*\n \n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-1.htm)\n\n31.2*\n \n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-2.htm)\n\n32.1**\n \n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm)\n\n32.2**\n \n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-2.htm)\n\n101.INS\n \nInline\nXBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within\nthe Inline XBRL document.\n\n101.SCH\n \nlnline\nXBRL Taxonomy Extension Schema With Embedded Linkbase Documents.\n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n \n\n*\nFiled herewith.\n\n**\nThis certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise\nsubject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under\nthe Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Registrant specifically incorporates\nit by reference.\n\n†\nIndicates management contract or compensatory arrangement.\n\n \n\n28\n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its\nbehalf by the undersigned, thereunto duly authorized**.**\n\n** **\n\n \n**Akari\nTherapeutics, Plc**\n\n \n \n \n\nDate:\nMay 19, 2026\nBy:\n*/s/\nAbizer Gaslightwala*\n\n \n** **\n**Abizer\nGaslightwala**\n\n \n** **\n**President\nand Chief Executive Officer**\n\n \n \n \n\n \nBy:\n*/s/\nKameel Farag*\n\nDate:\nMay 19, 2026\n \n**Kameel\nFarag**\n\n \n \n**Interim\nChief Financial Officer**\n\n \n\n29"}